ATLAS-2M: Switch to Long-Acting Injectable Cabotegravir + Rilpivirine Every 2 Mos Is Noninferior to Switch to Monthly Injections in Virologically Suppressed Patients at Wk 48

March 8-11, 2020; Boston, Massachusetts
Phase III data demonstrate that long-acting cabotegravir + rilpivirine injections every 2 months is noninferior to monthly injections at Week 48 in virologically suppressed patients with no prior virologic failure.
Format: Microsoft PowerPoint (.ppt)
File Size: 204 KB
Released: March 10, 2020

Acknowledgements

Provided by USF Health, in partnership with Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@clinicaloptions.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

This activity is supported by educational grants from
Gilead Sciences
Merck & Co., Inc.
ViiV Healthcare

Related Content

Vlog from Clinical Care Options (CCO) and Dr. Jehan Budak demonstrating HIV-ASSIST to guide ART selection in a HTE patient with HIV. Review of NRTI, NNRTI, PI, INSTI mutations, and more.

Jehan Budak, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Physician Assistants: maximum of 0.25 hour of AAPA Category ICME credit ABIM MOC: maximum of 0.25 Medical Knowledge MOC point(s) Released: July 27, 2021 Expired: July 26, 2022

Interim results from the Phase II CALIBRATE study of lenacapavir in treatment-naive PLWH, reported by Clinical Care Options (CCO) from IAS 2021

Released: July 24, 2021

Large, retrospective analysis supports the effectiveness and safety of dolutegravir-based regimens among children and adolescents, reported by Clinical Care Options (CCO) from IAS 2021

Released: July 22, 2021

IAS 2021 report from Clinical Care Options (CCO): CUSTOMIZE study shows that HCPs think monthly injectable CAB + RTV LA is feasible and acceptable despite COVID-19 disruptions

Released: July 22, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue